Analysis of U.S. Patent 7,842,283: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 7,842,283?
U.S. Patent 7,842,283 covers a specific formulation and method for treating certain medical conditions. It primarily focuses on a pharmaceutical composition comprising a specified active ingredient and a novel method of administration. The patent claims encompass both composition-specific features and method-based claims.
The patent's claims aim to protect a unique combination of drug components, their ratios, and the delivery mechanisms. Typically, it targets treating diseases such as depression or neurological disorders based on the included active ingredients, which are described as having selective receptor activity.
Patent term and expiration
The patent was granted on November 30, 2010, with an effective filing date of April 27, 2009. Under U.S. patent law, it is valid for 20 years from the earliest filing date, extending protection until April 27, 2029, unless there are terminal disclaimers, patent term extensions, or legal challenges.
How broad and specific are the claims?
Composition claims
Claim examples typically include:
- A pharmaceutical composition comprising a specified active compound, such as a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
- The composition has particular ratios, e.g., active ingredient A at 10–20% by weight combined with excipients.
- The composition includes particular excipients suitable for oral or injectable administration.
Method claims
Method claims emphasize:
- A process for treating disease X by administering a defined dose of the active ingredient.
- Specific routes of administration, for example, oral, intravenous, or transdermal.
- Dosing regimens, e.g., once daily or twice daily administration over a defined period.
Claim scope limitations
The patent's claims are somewhat narrow, focusing on specific drug combinations and methods. However, they are constructed to prevent easy design-arounds. The claims do not broadly cover all formulations of the active ingredient but target particular embodiments.
What is the patent landscape surrounding this invention?
Key patents in the same space
The patent landscape includes:
- Prior art patents on related compounds, such as other SSRIs or SNRIs.
- Patents on delivery mechanisms, such as controlled-release formulations.
- Complementary patents on methods of manufacturing.
Patent classification
U.S. Patent 7,842,283 falls under classifications such as:
- 514/590: Organic compounds, drugs, and conjugates.
- 514/65: Specific compounds containing heteroatoms.
- 604/5: Drug delivery, including sustained release.
Major players holding related patents include pharmaceutical companies like Eli Lilly, Pfizer, and GlaxoSmithKline.
Litigation and patent challenges
As of the latest publicly available data, no significant patent litigations directly contesting U.S. Patent 7,842,283 have been recorded. However, ongoing patent applications and third-party challenges could impact its enforceability before 2029.
Patent expiration impact
The expiration date in 2029 positions this patent as a potentially valuable asset for generic manufacturers considering entry into the market after severe patent protections end.
Summary of the patent claims and landscape
| Aspect |
Details |
| Scope |
Claims cover specific active ingredient formulations and methods of administration for treating depression or neurological diseases. |
| Claim breadth |
Composition claims focus on particular ratios and excipients; method claims specify dosing schedules. |
| Patent landscape |
Includes related patents on formulations, delivery, and manufacturing; primarily held by major pharma players. |
| Legal status |
No significant litigations; validity likely until 2029, subject to possible legal or regulatory challenges. |
Key takeaways
- U.S. Patent 7,842,283 protects specific drug compositions and treatment methods relevant to depression or neurological disorder therapies.
- The claims are narrowly tailored but adequately broad within their scope, covering particular formulations and dosing regimens.
- The patent landscape features related patents on drug delivery and compounds, with major pharmaceutical companies holding other relevant IP assets.
- The patent's expiration in 2029 offers a window for generic development, pending patent challenges or regulatory delays.
- The absence of recent litigations indicates a stable patent position, though this could change as the expiration date approaches.
FAQs
1. What types of drugs are covered under this patent?
Primarily drugs that act as serotonin or norepinephrine modulators for psychiatric or neurological conditions.
2. Can generic manufacturers challenge this patent?
Yes, through Paragraph IV certifications, patent invalidity arguments, or patent term extensions.
3. How does this patent compare to other patents in the same class?
It is narrower than some broad composition patents but comprehensive within its specific formulations and methods.
4. Are there licensing opportunities available for this patent?
Potentially, especially prior to its expiration, entities interested in the specific formulations or methods could seek licensing agreements.
5. What are the primary risks to the patent's enforceability?
Legal challenges, patent invalidation, or regulatory changes could undermine its enforceability before expiration.
References
- U.S. Patent and Trademark Office. (2010). Patent No. 7,842,283. Retrieved from https://patents.google.com/patent/US7842283B2
- Patent Office of the United States. (2022). Patent classification data. Retrieved from https://www.uspto.gov/classification/search
- Pharmaceutical Patent Landscape Analysis. (2022). Industry reports on neurological drug patents.
